Leukemia

Autografting with non-clonal mobilized hematopoietic progenitor cells in CML
TO THE EDITOR I have read the comments made by Thijsen et al 1 about our technique to mobilize non-clonal hematopoietic progenitor cells (HPC) in patients with chronic myeloid leukemia. The data reported by the authors refer to a paper published many years ago. 2 Meantime other papers have been published by us on this topic and it would be more useful and convenient to mention them as they summarize 10 years of experience on 185 patients. The results coming from these papers are the following: (1) Ph-negative collections are rare in accelerated/blastic phases of disease because non-clonal cells are no longer available in marrow and patients cannot withstand toxic therapy;
3 (2) in advanced phases of disease and generally in much pretreated patients with interferon, such a procedure requires long hospitalization and worse cell phereses; 4 (3) high rates of non-clonal collections are achieved earlier at diagnosis in untreated patients with interferon; 3,5 (4) the cytogenetic response on peripheral blood is correlated with Sokal score (excellent results in low and intermediate risk and worse results in high-risk patients); 3,5 (5) ICE/mini-ICE protocols determine the same Ph-negative peripheral blood collections but mini-ICE has more potential benefits because it may be administered in the outpatient facility, it is less GI toxic and shorter hospitalization is needed; 5 moreover, mini-ICE seems more effective than highdose hydroxyurea.
Diploid cells are most likely in pheresis 1 but at least two to three phereses are required to collect у2 × 10 6 CD34 + cells. We have treated 56 patients in the earlier phase of disease (at a median of 2 months from diagnosis) and not pretreated with interferon. The major part of non-clonal phereses had BCR-ABL transcript numbers varying from a median of 100/g RNA in the first/second leukaphereses, to 500/g RNA in the subsequent collections. 6 BCR-ABL/ABL ratio values showed similar kinetics. 6 Forty-two patients were autografted. No patient died as a consequence of the treatment, also because all patients were treated with cephalosporins plus aminoglycosides and amphotericin B (± vancomycin if coagulasenegative staphylococcus was found) when the patient reached р1 × 10 9 /1 neutrophils after high-dose therapy. Thirty-eight patients are alive 6 to 90 months (median, 33 months) after autografting. Ten patients are in complete cytogenetic remission at a median of 35 months (range, 2 to 58 months), with a median ratio of BCR-ABL/ABL of 0.002 (range, Ͻ0.001 to 0.01). Eight patients are alive with less than 50% Ph-positive cells in the marrow at a median of 23 months (range, 7 to 62 months). These data confirm our previous results published on 30 patients. 7 A correlation between the low values of BCR-ABL/ABL ratio in the reinfused cells and the achievement of cytogenetic remission after autografting (X 3 test, P = 0.01) was also demonstrated. 6 The results achieved by our group have been recently confirmed by three other teams not cited in the review. [8] [9] [10] At the end, our experience with idarubicin-containing regimens on 185 patients with CML in different phases of disease, confirm that it is possible to collect nonclonal HSC; moreover, these cells are able to engraft after transplant and to maintain Ph-negativity for a long time in some of them. Clearly new strategies to improve these results could develop from the tyrosine kinase inhibitors; in particular, the PTK inhibitor CGP 57148 has been demonstrated to possess a high specificity for the Abl PTK and it was able to reduce BCR-ABL positive CFU-GM colony growth whereas normal colony growth was hardly affected. If these data are further confirmed, an interesting study could be to use this inhibitor upfront at diagnosis. The patients who have not had a complete response to STI after 4-6 months, could be treated with mini-ICE/HSC mobilization/autografting to be followed by STI/interferon.
